Biofrigas (BIOF) Q2 2025 earnings summary

Executive summary

• Focus during Q2 2025 was on verification and test runs of the first customer delivery, capital raising, and market development.

• Extensive testing of the new facility showed promising results, aligning with technical expectations.

• Strengthened sales resources and prepared for a key scale-up phase, with a CEO transition planned for September.

Financial highlights

• Net sales for Q2 2025 were KSEK 0, down from KSEK 3,008 year-over-year; for H1 2025, net sales were KSEK 256 (3,008).

• Result after financial items for Q2 was KSEK -3,341 (-3,087); for H1, KSEK -5,900 (-4,858).

• Earnings per share for Q2 was -0.06 SEK (-0.23); for H1, -0.10 SEK (-0.35).

• Equity ratio at June 30, 2025, was 76.1% (66.2%).

• Cash flow for Q2 was KSEK 1,859 (4,177); for H1, KSEK -3,567 (1,547).

Outlook and guidance

• The company is entering a critical scale-up phase, with a focus on completing the first customer delivery and securing new business.

• Patent processes are ongoing in China and Europe, with a US patent granted, supporting future commercial opportunities.